CRISPR Therapeutics AG (NASDAQ: CRSP)

CRISPR Therapeutics AG, recognized by its ticker symbol CRSP, is a prominent company specializing in the development of CRISPR/Cas9-based therapeutics. Operating within the biotechnology industry, CRISPR Therapeutics is dedicated to harnessing the power of gene editing to disrupt, delete, correct, and insert genes for the treatment of genetic diseases and the engineering of advanced cellular therapies. The company's main business activities encompass the development of gene-edited cell therapies for various diseases, including hemoglobinopathies, immuno-oncology and autoimmune, in vivo approaches, and type 1 diabetes.

CRISPR Therapeutics generates revenue through the development and commercialization of gene-edited cell therapies. The company's primary product is CASGEVY, a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for the treatment of severe sickle cell disease and beta thalassemia. CASGEVY is the first-ever approved CRISPR-based gene-editing therapy in the world and has received approvals in the United States and multiple other countries worldwide.

In the hemoglobinopathies franchise, CASGEVY is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy targeting the erythroid-specific enhancer region of the BCL11A gene. This edit results in the production of high levels of fetal hemoglobin in red blood cells, compensating for the defective adult hemoglobin in patients with sickle cell disease and beta thalassemia. CASGEVY has been approved in the United States and multiple other countries worldwide for the treatment of eligible patients with severe sickle cell disease and beta thalassemia.

In the immuno-oncology and autoimmune franchise, CRISPR Therapeutics is advancing multiple next-generation gene-edited cell therapy programs for oncology and autoimmune indications. The company is developing allogeneic chimeric antigen receptor T cell (CAR T) candidates for the treatment of hematological and solid tumor cancers and autoimmune diseases. Additionally, CRISPR Therapeutics is working on in vivo gene editing therapies for the treatment of cardiovascular disease and other common diseases.

In the in vivo approaches franchise, CRISPR Therapeutics' strategy focuses on gene disruption and whole gene correction. The company has established a leading platform for in vivo gene editing and is rapidly advancing a broad portfolio of in vivo programs. The initial in vivo programs target the liver, utilizing validated lipid nanoparticle delivery technologies, aiming to treat diseases where a strong therapeutic effect can be achieved by safely disrupting a gene with well-understood genetic association.

In the type 1 diabetes franchise, CRISPR Therapeutics is advancing a series of programs focused on the development of gene-edited stem cell-derived therapies for the treatment of type 1 diabetes. The company believes its gene editing capabilities have the potential to enable a beta-cell replacement product candidate that may deliver durable benefit to patients without the need for long-term immunosuppression.

CRISPR Therapeutics has established a portfolio of therapeutic programs spanning four core franchises and has partnered strategically to broaden the indications it can pursue and accelerate programs by accessing specific technologies and/or disease-area expertise. The company has entered into collaborations with Vertex, ViaCyte, and other partners to develop and commercialize gene-edited cell therapies for various diseases.